表紙
市場調查報告書
商品編碼
1068779

HER2(人類表皮生長因子受體2)抑制劑的全球市場(2022年∼2026年)

Global HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market 2022-2026

出版日期: | 出版商: TechNavio (Infiniti Research Ltd.) | 英文 120 Pages | 訂單完成後即時交付

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球HER2(人類表皮生長因子受體2)抑制劑的市場規模,在2022年∼2026年的預測期間內,預計將以8.95%的年複合成長率推移,並成長到80億美元。

市場成長的主要因素有乳腺癌和胃癌的高發病率、最近的批准以及對乳腺癌的認識的提高。

本報告提供全球HER2(人類表皮生長因子受體2)抑制劑市場調查,提供市場概要,市場規模和預測,趨勢,成長要素及課題,客戶形勢,產品·各地區的分析,再加上業者情勢及供應商分析等資訊。

目錄

第1章 摘要整理

  • 市場概要

第2章 市場形勢

  • 市場生態系統

第3章 市場規模

  • 市場定義
  • 市場區隔分析
  • 市場規模:2021年
  • 市場預測:從2021年∼2026年的預測

第4章 波特的五力分析

  • 五力摘要
  • 買方議價能力
  • 供給企業談判力
  • 新加入廠商業者的威脅
  • 替代品的威脅
  • 對手的威脅
  • 市場情況

第5章 各產品的市場區隔

  • 市場明細
  • 各產品的比較
  • 單劑療法:市場規模與預測(2021年∼2026年)
  • 聯合治療:市場規模與預測(2021年∼2026年)
  • 各產品的市場機會

第6章 客戶形勢

  • 客戶形勢概要

第7章 各地區形勢

  • 各地區市場區隔
  • 各地區比較
  • 北美:市場規模與預測(2021年∼2026年)
  • 歐洲:市場規模與預測(2021年∼2026年)
  • 亞洲:市場規模與預測(2021年∼2026年)
  • 其他地區:市場規模與預測(2021年∼2026年)
  • 美國:市場規模與預測(2021年∼2026年)
  • 德國:市場規模與預測(2021年∼2026年)
  • 英國:市場規模與預測(2021年∼2026年)
  • 中國:市場規模與預測(2021年∼2026年)
  • 加拿大:市場規模與預測(2021年∼2026年)
  • 各地區形勢的市場機會

第8章 促進因素,課題,及趨勢

  • 推動市場要素
  • 市場課題
  • 推動因素與課題的影響
  • 市場趨勢

第9章 業者情勢

  • 概要
  • 業者情勢
  • 混亂形勢
  • 產業的風險

第10章 供應商分析

  • 交易廠商
  • 供應商的市場定位
  • Amgen Inc.
  • AryoGen Pharmed
  • Biocon Ltd.
  • Celltrion Healthcare Co. Ltd.
  • F. Hoffmann La Roche Ltd.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Puma Biotechnology Inc.
  • Viatris Inc.

第11章 附錄

  • 調查範圍
  • 包含與除外清單
  • 美金的匯率
  • 調查手法
  • 簡稱的清單
目錄
Product Code: IRTNTR72960

Technavio has been monitoring the HER2 (human epidermal growth factor receptor 2) inhibitors market and it is poised to grow by $ 8.00 bn during 2022-2026 progressing at a CAGR of 8.95% during the forecast period. Our report on the HER2 (human epidermal growth factor receptor 2) inhibitors market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the high prevalence of breast cancer and gastric cancer, recent approvals, and growing awareness about breast cancer.

The HER2 (human epidermal growth factor receptor 2) inhibitors market analysis includes the product segment and geographic landscape.

Technavio's HER2 (human epidermal growth factor receptor 2) inhibitors market is segmented as below:

By Product

  • Monotherapy
  • Combination therapy

By Geographical Landscape

  • North America
  • Europe
  • Asia
  • Rest of World (ROW)

This study identifies the patient assistance programs as one of the prime reasons driving the HER2 (human epidermal growth factor receptor 2) inhibitors market growth during the next few years. Also, the introduction of new diagnostics for breast cancer and strategic alliances will lead to sizable demand in the market.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on HER2 (human epidermal growth factor receptor 2) inhibitors market covers the following areas:

  • HER2 (human epidermal growth factor receptor 2) inhibitors market sizing
  • HER2 (human epidermal growth factor receptor 2) inhibitors market forecast
  • HER2 (human epidermal growth factor receptor 2) inhibitors market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading HER2 (human epidermal growth factor receptor 2) inhibitors market vendors that include Samsung BioLogicsA Co. Ltd., Amgen Inc., AryoGen Pharmed, AstraZeneca Plc, Biocon Ltd., Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Celltrion Healthcare Co. Ltd., Dr. Reddys Laboratories Ltd., F. Hoffmann La Roche Ltd., Intas Pharmaceuticals Ltd., JSC BIOCAD, Merck KGaA, Novartis AG, Pfizer Inc., Puma Biotechnology Inc., Shanghai Henlius Biotech Inc., Teva Pharmaceutical Industries Ltd., and Viatris Inc. Also, the HER2 (human epidermal growth factor receptor 2) inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1 Executive Summary

  • 1.1 Market overview
  • Exhibit 01: Executive Summary - Chart on Market Overview
  • Exhibit 02: Executive Summary - Data Table on Market Overview
  • Exhibit 03: Executive Summary - Chart on Global Market Characteristics
  • Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
  • Exhibit 05: Executive Summary - Chart on Market Segmentation by Product
  • Exhibit 06: Executive Summary - Chart on Incremental Growth
  • Exhibit 07: Executive Summary - Data Table on Incremental Growth
  • Exhibit 08: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
  • Exhibit 09: Parent market
  • Exhibit 10: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
  • Exhibit 11: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
  • Exhibit 12: Market segments
  • 3.3 Market size 2021
  • 3.4 Market outlook: Forecast for 2021-2026
  • Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
  • Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
  • Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
  • Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

4 Five Forces Analysis

  • 4.1 Five forces summary
  • Exhibit 17: Five forces analysis - Comparison between2021 and 2026
  • 4.2 Bargaining power of buyers
  • Exhibit 18: Chart on Bargaining power of buyers - Impact of key factors 2021 and 2026
  • 4.3 Bargaining power of suppliers
  • Exhibit 19: Bargaining power of suppliers - Impact of key factors in 2021 and 2026
  • 4.4 Threat of new entrants
  • Exhibit 20: Threat of new entrants - Impact of key factors in 2021 and 2026
  • 4.5 Threat of substitutes
  • Exhibit 21: Threat of substitutes - Impact of key factors in 2021 and 2026
  • 4.6 Threat of rivalry
  • Exhibit 22: Threat of rivalry - Impact of key factors in 2021 and 2026
  • 4.7 Market condition
  • Exhibit 23: Chart on Market condition - Five forces 2021 and 2026

5 Market Segmentation by Product

  • 5.1 Market segments
  • Exhibit 24: Chart on Product - Market share 2021-2026 (%)
  • Exhibit 25: Data Table on Product - Market share 2021-2026 (%)
  • 5.2 Comparison by Product
  • Exhibit 26: Chart on Comparison by Product
  • Exhibit 27: Data Table on Comparison by Product
  • 5.3 Monotherapy - Market size and forecast 2021-2026
  • Exhibit 28: Chart on Monotherapy - Market size and forecast 2021-2026 ($ million)
  • Exhibit 29: Data Table on Monotherapy - Market size and forecast 2021-2026 ($ million)
  • Exhibit 30: Chart on Monotherapy - Year-over-year growth 2021-2026 (%)
  • Exhibit 31: Data Table on Monotherapy - Year-over-year growth 2021-2026 (%)
  • 5.4 Combination therapy - Market size and forecast 2021-2026
  • Exhibit 32: Chart on Combination therapy - Market size and forecast 2021-2026 ($ million)
  • Exhibit 33: Data Table on Combination therapy - Market size and forecast 2021-2026 ($ million)
  • Exhibit 34: Chart on Combination therapy - Year-over-year growth 2021-2026 (%)
  • Exhibit 35: Data Table on Combination therapy - Year-over-year growth 2021-2026 (%)
  • 5.5 Market opportunity by Product
  • Exhibit 36: Market opportunity by Product ($ million)

6 Customer Landscape

  • 6.1 Customer landscape overview
  • Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

7 Geographic Landscape

  • 7.1 Geographic segmentation
  • Exhibit 38: Chart on Market share By Geographical Landscape 2021-2026 (%)
  • Exhibit 39: Data Table on Market share By Geographical Landscape 2021-2026 (%)
  • 7.2 Geographic comparison
  • Exhibit 40: Chart on Geographic comparison
  • Exhibit 41: Data Table on Geographic comparison
  • 7.3 North America - Market size and forecast 2021-2026
  • Exhibit 42: Chart on North America - Market size and forecast 2021-2026 ($ million)
  • Exhibit 43: Data Table on North America - Market size and forecast 2021-2026 ($ million)
  • Exhibit 44: Chart on North America - Year-over-year growth 2021-2026 (%)
  • Exhibit 45: Data Table on North America - Year-over-year growth 2021-2026 (%)
  • 7.4 Europe - Market size and forecast 2021-2026
  • Exhibit 46: Chart on Europe - Market size and forecast 2021-2026 ($ million)
  • Exhibit 47: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
  • Exhibit 48: Chart on Europe - Year-over-year growth 2021-2026 (%)
  • Exhibit 49: Data Table on Europe - Year-over-year growth 2021-2026 (%)
  • 7.5 Asia - Market size and forecast 2021-2026
  • Exhibit 50: Chart on Asia - Market size and forecast 2021-2026 ($ million)
  • Exhibit 51: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
  • Exhibit 52: Chart on Asia - Year-over-year growth 2021-2026 (%)
  • Exhibit 53: Data Table on Asia - Year-over-year growth 2021-2026 (%)
  • 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
  • Exhibit 54: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
  • Exhibit 55: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
  • Exhibit 56: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
  • Exhibit 57: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
  • 7.7 US - Market size and forecast 2021-2026
  • Exhibit 58: Chart on US - Market size and forecast 2021-2026 ($ million)
  • Exhibit 59: Data Table on US - Market size and forecast 2021-2026 ($ million)
  • Exhibit 60: Chart on US - Year-over-year growth 2021-2026 (%)
  • Exhibit 61: Data Table on US - Year-over-year growth 2021-2026 (%)
  • 7.8 Germany - Market size and forecast 2021-2026
  • Exhibit 62: Chart on Germany - Market size and forecast 2021-2026 ($ million)
  • Exhibit 63: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
  • Exhibit 64: Chart on Germany - Year-over-year growth 2021-2026 (%)
  • Exhibit 65: Data Table on Germany - Year-over-year growth 2021-2026 (%)
  • 7.9 UK - Market size and forecast 2021-2026
  • Exhibit 66: Chart on UK - Market size and forecast 2021-2026 ($ million)
  • Exhibit 67: Data Table on UK - Market size and forecast 2021-2026 ($ million)
  • Exhibit 68: Chart on UK - Year-over-year growth 2021-2026 (%)
  • Exhibit 69: Data Table on UK - Year-over-year growth 2021-2026 (%)
  • 7.10 China - Market size and forecast 2021-2026
  • Exhibit 70: Chart on China - Market size and forecast 2021-2026 ($ million)
  • Exhibit 71: Data Table on China - Market size and forecast 2021-2026 ($ million)
  • Exhibit 72: Chart on China - Year-over-year growth 2021-2026 (%)
  • Exhibit 73: Data Table on China - Year-over-year growth 2021-2026 (%)
  • 7.11 Canada - Market size and forecast 2021-2026
  • Exhibit 74: Chart on Canada - Market size and forecast 2021-2026 ($ million)
  • Exhibit 75: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
  • Exhibit 76: Chart on Canada - Year-over-year growth 2021-2026 (%)
  • Exhibit 77: Data Table on Canada - Year-over-year growth 2021-2026 (%)
  • 7.12 Market opportunity By Geographical Landscape
  • Exhibit 78: Market opportunity By Geographical Landscape ($ million)

8 Drivers, Challenges, and Trends

  • 8.1 Market drivers
  • 8.2 Market challenges
  • 8.3 Impact of drivers and challenges
  • Exhibit 79: Impact of drivers and challenges in 2021 and 2026
  • 8.4 Market trends

9 Vendor Landscape

  • 9.1 Overview
  • 9.2 Vendor landscape
  • Exhibit 80: Overview on Criticality of inputs and Factors of differentiation
  • 9.3 Landscape disruption
  • Exhibit 81: Overview on factors of disruption
  • 9.4 Industry risks
  • Exhibit 82: Impact of key risks on business

10 Vendor Analysis

  • 10.1 Vendors covered
  • Exhibit 83: Vendors covered
  • 10.2 Market positioning of vendors
  • Exhibit 84: Matrix on vendor position and classification
  • 10.3 Amgen Inc.
  • Exhibit 85: Amgen Inc. - Overview
  • Exhibit 86: Amgen Inc. - Product / Service
  • Exhibit 87: Amgen Inc. - Key offerings
  • 10.4 AryoGen Pharmed
  • Exhibit 88: AryoGen Pharmed - Overview
  • Exhibit 89: AryoGen Pharmed - Product / Service
  • Exhibit 90: AryoGen Pharmed - Key offerings
  • 10.5 Biocon Ltd.
  • Exhibit 91: Biocon Ltd. - Overview
  • Exhibit 92: Biocon Ltd. - Business segments
  • Exhibit 93: Biocon Ltd. - Key offerings
  • Exhibit 94: Biocon Ltd. - Segment focus
  • 10.6 Celltrion Healthcare Co. Ltd.
  • Exhibit 95: Celltrion Healthcare Co. Ltd. - Overview
  • Exhibit 96: Celltrion Healthcare Co. Ltd. - Product / Service
  • Exhibit 97: Celltrion Healthcare Co. Ltd. - Key offerings
  • 10.7 F. Hoffmann La Roche Ltd.
  • Exhibit 98: F. Hoffmann La Roche Ltd. - Overview
  • Exhibit 99: F. Hoffmann La Roche Ltd. - Business segments
  • Exhibit 100: F. Hoffmann La Roche Ltd. - Key news
  • Exhibit 101: F. Hoffmann La Roche Ltd. - Key offerings
  • Exhibit 102: F. Hoffmann La Roche Ltd. - Segment focus
  • 10.8 Merck KGaA
  • Exhibit 103: Merck KGaA - Overview
  • Exhibit 104: Merck KGaA - Business segments
  • Exhibit 105: Merck KGaA - Key news
  • Exhibit 106: Merck KGaA - Key offerings
  • Exhibit 107: Merck KGaA - Segment focus
  • 10.9 Novartis AG
  • Exhibit 108: Novartis AG - Overview
  • Exhibit 109: Novartis AG - Business segments
  • Exhibit 110: Novartis AG - Key offerings
  • Exhibit 111: Novartis AG - Segment focus
  • 10.10 Pfizer Inc.
  • Exhibit 112: Pfizer Inc. - Overview
  • Exhibit 113: Pfizer Inc. - Product / Service
  • Exhibit 114: Pfizer Inc. - Key news
  • Exhibit 115: Pfizer Inc. - Key offerings
  • 10.11 Puma Biotechnology Inc.
  • Exhibit 116: Puma Biotechnology Inc. - Overview
  • Exhibit 117: Puma Biotechnology Inc. - Business segments
  • Exhibit 118: Puma Biotechnology Inc. - Key news
  • Exhibit 119: Puma Biotechnology Inc. - Key offerings
  • Exhibit 120: Puma Biotechnology Inc. - Segment focus
  • 10.12 Viatris Inc.
  • Exhibit 121: Viatris Inc. - Overview
  • Exhibit 122: Viatris Inc. - Business segments
  • Exhibit 123: Viatris Inc. - Key offerings
  • Exhibit 124: Viatris Inc. - Segment focus

11 Appendix

  • 11.1 Scope of the report
  • 11.2 Inclusions and exclusions checklist
  • Exhibit 125: Inclusions checklist
  • Exhibit 126: Exclusions checklist
  • 11.3 Currency conversion rates for US$
  • Exhibit 127: Currency conversion rates for US$
  • 11.4 Research methodology
  • Exhibit 128: Research methodology
  • Exhibit 129: Validation techniques employed for market sizing
  • Exhibit 130: Information sources
  • 11.5 List of abbreviations
  • Exhibit 131: List of abbreviations

Exhibits

  • Exhibits1: Executive Summary - Chart on Market Overview
  • Exhibits2: Executive Summary - Data Table on Market Overview
  • Exhibits3: Executive Summary - Chart on Global Market Characteristics
  • Exhibits4: Executive Summary - Chart on Market By Geographical Landscape
  • Exhibits5: Executive Summary - Chart on Market Segmentation by Product
  • Exhibits6: Executive Summary - Chart on Incremental Growth
  • Exhibits7: Executive Summary - Data Table on Incremental Growth
  • Exhibits8: Executive Summary - Chart on Vendor Market Positioning
  • Exhibits9: Parent market
  • Exhibits10: Market Characteristics
  • Exhibits11: Offerings of vendors included in the market definition
  • Exhibits12: Market segments
  • Exhibits13: Chart on Global - Market size and forecast 2021-2026 ($ million)
  • Exhibits14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
  • Exhibits15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
  • Exhibits16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)
  • Exhibits17: Five forces analysis - Comparison between2021 and 2026
  • Exhibits18: Chart on Bargaining power of buyers - Impact of key factors 2021 and 2026
  • Exhibits19: Bargaining power of suppliers - Impact of key factors in 2021 and 2026
  • Exhibits20: Threat of new entrants - Impact of key factors in 2021 and 2026
  • Exhibits21: Threat of substitutes - Impact of key factors in 2021 and 2026
  • Exhibits22: Threat of rivalry - Impact of key factors in 2021 and 2026
  • Exhibits23: Chart on Market condition - Five forces 2021 and 2026
  • Exhibits24: Chart on Product - Market share 2021-2026 (%)
  • Exhibits25: Data Table on Product - Market share 2021-2026 (%)
  • Exhibits26: Chart on Comparison by Product
  • Exhibits27: Data Table on Comparison by Product
  • Exhibits28: Chart on Monotherapy - Market size and forecast 2021-2026 ($ million)
  • Exhibits29: Data Table on Monotherapy - Market size and forecast 2021-2026 ($ million)
  • Exhibits30: Chart on Monotherapy - Year-over-year growth 2021-2026 (%)
  • Exhibits31: Data Table on Monotherapy - Year-over-year growth 2021-2026 (%)
  • Exhibits32: Chart on Combination therapy - Market size and forecast 2021-2026 ($ million)
  • Exhibits33: Data Table on Combination therapy - Market size and forecast 2021-2026 ($ million)
  • Exhibits34: Chart on Combination therapy - Year-over-year growth 2021-2026 (%)
  • Exhibits35: Data Table on Combination therapy - Year-over-year growth 2021-2026 (%)
  • Exhibits36: Market opportunity by Product ($ million)
  • Exhibits37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Exhibits38: Chart on Market share By Geographical Landscape 2021-2026 (%)
  • Exhibits39: Data Table on Market share By Geographical Landscape 2021-2026 (%)
  • Exhibits40: Chart on Geographic comparison
  • Exhibits41: Data Table on Geographic comparison
  • Exhibits42: Chart on North America - Market size and forecast 2021-2026 ($ million)
  • Exhibits43: Data Table on North America - Market size and forecast 2021-2026 ($ million)
  • Exhibits44: Chart on North America - Year-over-year growth 2021-2026 (%)
  • Exhibits45: Data Table on North America - Year-over-year growth 2021-2026 (%)
  • Exhibits46: Chart on Europe - Market size and forecast 2021-2026 ($ million)
  • Exhibits47: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
  • Exhibits48: Chart on Europe - Year-over-year growth 2021-2026 (%)
  • Exhibits49: Data Table on Europe - Year-over-year growth 2021-2026 (%)
  • Exhibits50: Chart on Asia - Market size and forecast 2021-2026 ($ million)
  • Exhibits51: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
  • Exhibits52: Chart on Asia - Year-over-year growth 2021-2026 (%)
  • Exhibits53: Data Table on Asia - Year-over-year growth 2021-2026 (%)
  • Exhibits54: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
  • Exhibits55: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
  • Exhibits56: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
  • Exhibits57: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
  • Exhibits58: Chart on US - Market size and forecast 2021-2026 ($ million)
  • Exhibits59: Data Table on US - Market size and forecast 2021-2026 ($ million)
  • Exhibits60: Chart on US - Year-over-year growth 2021-2026 (%)
  • Exhibits61: Data Table on US - Year-over-year growth 2021-2026 (%)
  • Exhibits62: Chart on Germany - Market size and forecast 2021-2026 ($ million)
  • Exhibits63: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
  • Exhibits64: Chart on Germany - Year-over-year growth 2021-2026 (%)
  • Exhibits65: Data Table on Germany - Year-over-year growth 2021-2026 (%)
  • Exhibits66: Chart on UK - Market size and forecast 2021-2026 ($ million)
  • Exhibits67: Data Table on UK - Market size and forecast 2021-2026 ($ million)
  • Exhibits68: Chart on UK - Year-over-year growth 2021-2026 (%)
  • Exhibits69: Data Table on UK - Year-over-year growth 2021-2026 (%)
  • Exhibits70: Chart on China - Market size and forecast 2021-2026 ($ million)
  • Exhibits71: Data Table on China - Market size and forecast 2021-2026 ($ million)
  • Exhibits72: Chart on China - Year-over-year growth 2021-2026 (%)
  • Exhibits73: Data Table on China - Year-over-year growth 2021-2026 (%)
  • Exhibits74: Chart on Canada - Market size and forecast 2021-2026 ($ million)
  • Exhibits75: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
  • Exhibits76: Chart on Canada - Year-over-year growth 2021-2026 (%)
  • Exhibits77: Data Table on Canada - Year-over-year growth 2021-2026 (%)
  • Exhibits78: Market opportunity By Geographical Landscape ($ million)
  • Exhibits79: Impact of drivers and challenges in 2021 and 2026
  • Exhibits80: Overview on Criticality of inputs and Factors of differentiation
  • Exhibits81: Overview on factors of disruption
  • Exhibits82: Impact of key risks on business
  • Exhibits83: Vendors covered
  • Exhibits84: Matrix on vendor position and classification
  • Exhibits85: Amgen Inc. - Overview
  • Exhibits86: Amgen Inc. - Product / Service
  • Exhibits87: Amgen Inc. - Key offerings
  • Exhibits88: AryoGen Pharmed - Overview
  • Exhibits89: AryoGen Pharmed - Product / Service
  • Exhibits90: AryoGen Pharmed - Key offerings
  • Exhibits91: Biocon Ltd. - Overview
  • Exhibits92: Biocon Ltd. - Business segments
  • Exhibits93: Biocon Ltd. - Key offerings
  • Exhibits94: Biocon Ltd. - Segment focus
  • Exhibits95: Celltrion Healthcare Co. Ltd. - Overview
  • Exhibits96: Celltrion Healthcare Co. Ltd. - Product / Service
  • Exhibits97: Celltrion Healthcare Co. Ltd. - Key offerings
  • Exhibits98: F. Hoffmann La Roche Ltd. - Overview
  • Exhibits99: F. Hoffmann La Roche Ltd. - Business segments
  • Exhibits100: F. Hoffmann La Roche Ltd. - Key news
  • Exhibits101: F. Hoffmann La Roche Ltd. - Key offerings
  • Exhibits102: F. Hoffmann La Roche Ltd. - Segment focus
  • Exhibits103: Merck KGaA - Overview
  • Exhibits104: Merck KGaA - Business segments
  • Exhibits105: Merck KGaA - Key news
  • Exhibits106: Merck KGaA - Key offerings
  • Exhibits107: Merck KGaA - Segment focus
  • Exhibits108: Novartis AG - Overview
  • Exhibits109: Novartis AG - Business segments
  • Exhibits110: Novartis AG - Key offerings
  • Exhibits111: Novartis AG - Segment focus
  • Exhibits112: Pfizer Inc. - Overview
  • Exhibits113: Pfizer Inc. - Product / Service
  • Exhibits114: Pfizer Inc. - Key news
  • Exhibits115: Pfizer Inc. - Key offerings
  • Exhibits116: Puma Biotechnology Inc. - Overview
  • Exhibits117: Puma Biotechnology Inc. - Business segments
  • Exhibits118: Puma Biotechnology Inc. - Key news
  • Exhibits119: Puma Biotechnology Inc. - Key offerings
  • Exhibits120: Puma Biotechnology Inc. - Segment focus
  • Exhibits121: Viatris Inc. - Overview
  • Exhibits122: Viatris Inc. - Business segments
  • Exhibits123: Viatris Inc. - Key offerings
  • Exhibits124: Viatris Inc. - Segment focus
  • Exhibits125: Inclusions checklist
  • Exhibits126: Exclusions checklist
  • Exhibits127: Currency conversion rates for US$
  • Exhibits128: Research methodology
  • Exhibits129: Validation techniques employed for market sizing
  • Exhibits130: Information sources
  • Exhibits131: List of abbreviations